Angela Falbo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Angela Falbo has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Stefano Palomba
Department of Medical-Surgical Sciences and Translational Medicine, University Sapienza of Rome, Rome, 00185, Italy.
11 shared publications - Giovanni Battista La Sala
Unit of Obstetrics and Gynecology, IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Dept. of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Reggio Emilia, Italy
7 shared publications - Fulvio Zullo
Unit of Obstetrics and Gynecology, Department of Experimental and Clinical Medicine, “Magna Graecia” University, 88100 Catanzaro, Italy
5 shared publications - Francesco Orio
Endocrinology, Department of Sports Science and Wellness, “Parthenope” University of Naples, 80133 Naples, Italy
3 shared publications Achille Tolino
2 shared publications- Achille Tolino
Department of Obstetrics & Gynecology, University "Federico II" of Naples, Naples, Italy
2 shared publications
Latest Publications
- 3 February 2018
- Published by Springer Nature
- p. 135-152
Insulin-Sensitising Drugs
- 1 October 2016
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 71 (10) , 575-576
“The More the Better” Paradox of Antenatal Ultrasound Examinations in Low-Risk Pregnancy
- 1 October 2016
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 71 (10) , 575-576
“The More the Better” Paradox of Antenatal Ultrasound Examinations in Low-Risk Pregnancy
- 10 February 2016
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 33 (07) , 646-657
“The More the Better” Paradox of Antenatal Ultrasound Examinations in Low-Risk Pregnancy
Objective To investigate whether different antenatal care models could account for differences in operative delivery rates and adverse neonatal outcomes among low-risk pregnant women, and to identify independent variables associated with delivery modes and adverse neonatal outcomes. Study design Retrospective cohort from a single center of singleton, term, live births between January 2012 and June 2014. Rates of cesarean deliveries, operative vaginal deliveries, and neonatal morbidities were analyzed among women followed by private obstetrician-gynecologists versus national health system providers (certified nurse midwifes supervised by obstetrician-gynecologists), and adjusted for potential confounders. Results Among the 2,831 women in our cohort, obstetric and neonatal outcomes were independent of obstetric providers. After we controlled for confounders, private patients having more than four antenatal ultrasound examinations were more likely to undergo cesarean delivery than public patients with four or fewer sonographic assessments (five to eight prenatal scans: relative risk ratio, 3.3; 95% confidence interval [CI] 1.4–8; nine or more prenatal scans: relative risk ratio, 4.1; 95% CI 1.2–14). Conclusions Multiple prenatal ultrasound examinations in low-risk obstetric populations appear to be an independent and potentially modifiable risk factor for cesarean deliveries.
- 10 February 2016
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 33 (07) , 646-657
“The More the Better” Paradox of Antenatal Ultrasound Examinations in Low-Risk Pregnancy
Objective To investigate whether different antenatal care models could account for differences in operative delivery rates and adverse neonatal outcomes among low-risk pregnant women, and to identify independent variables associated with delivery modes and adverse neonatal outcomes. Study design Retrospective cohort from a single center of singleton, term, live births between January 2012 and June 2014. Rates of cesarean deliveries, operative vaginal deliveries, and neonatal morbidities were analyzed among women followed by private obstetrician-gynecologists versus national health system providers (certified nurse midwifes supervised by obstetrician-gynecologists), and adjusted for potential confounders. Results Among the 2,831 women in our cohort, obstetric and neonatal outcomes were independent of obstetric providers. After we controlled for confounders, private patients having more than four antenatal ultrasound examinations were more likely to undergo cesarean delivery than public patients with four or fewer sonographic assessments (five to eight prenatal scans: relative risk ratio, 3.3; 95% confidence interval [CI] 1.4–8; nine or more prenatal scans: relative risk ratio, 4.1; 95% CI 1.2–14). Conclusions Multiple prenatal ultrasound examinations in low-risk obstetric populations appear to be an independent and potentially modifiable risk factor for cesarean deliveries.
- 16 July 2014
- Published by Bentham Science Publishers Ltd. in Clinical Immunology, Endocrine & Metabolic Drugs
- Vol. 1 (1) , 2-10
Clomiphene Citrate, Metformin or Aromatase Inhibitors for Anovulatory Infertility in Women with Polycystic Ovary Syndrome (PCOS): A Systematic Review of Meta-analyses and Randomized Controlled Trials
Background: Several drugs are actually used for treating women with polycystic ovary syndrome (PCOS). These included mainly clomiphene citrate (CC), metformin or aromatase inhibitors (AIs). Objectives: To review systematically the literature for meta-analyses and randomized controlled trials (RCTs) in order to clarify evidence based indications for the use of CC, metformin and AIs in the treatment of infertility in anovulatory patients with PCOS. Search Strategy: We searched and reviewed until September 2012 the main databases available. Selection Criteria: Meta-analyses and RCTs. Live-birth rate was considered as primary end-point. Data Collection and Analysis: Authors independently reviewed and extracted the data. Main Results: Fourteen meta-analyses and nine additional RCTs were analyzed showing heterogeneous results for several treatment comparisons. Conclusions: In infertile obese PCOS patients, the CC should be still considered the drugs of choice for inducing ovulation. Letrozole, even if is the only AI supported by evidence-based data, is not better than CC in therapy naïve patients. In patients with CC resistance, metformin plus CC improves significantly the reproductive outcomes, with particular regard for obese subjects.
- 16 July 2014
- Published by Bentham Science Publishers Ltd. in Clinical Immunology, Endocrine & Metabolic Drugs
- Vol. 1 (1) , 2-10
Clomiphene Citrate, Metformin or Aromatase Inhibitors for Anovulatory Infertility in Women with Polycystic Ovary Syndrome (PCOS): A Systematic Review of Meta-analyses and Randomized Controlled Trials
Background: Several drugs are actually used for treating women with polycystic ovary syndrome (PCOS). These included mainly clomiphene citrate (CC), metformin or aromatase inhibitors (AIs). Objectives: To review systematically the literature for meta-analyses and randomized controlled trials (RCTs) in order to clarify evidence based indications for the use of CC, metformin and AIs in the treatment of infertility in anovulatory patients with PCOS. Search Strategy: We searched and reviewed until September 2012 the main databases available. Selection Criteria: Meta-analyses and RCTs. Live-birth rate was considered as primary end-point. Data Collection and Analysis: Authors independently reviewed and extracted the data. Main Results: Fourteen meta-analyses and nine additional RCTs were analyzed showing heterogeneous results for several treatment comparisons. Conclusions: In infertile obese PCOS patients, the CC should be still considered the drugs of choice for inducing ovulation. Letrozole, even if is the only AI supported by evidence-based data, is not better than CC in therapy naïve patients. In patients with CC resistance, metformin plus CC improves significantly the reproductive outcomes, with particular regard for obese subjects.
- Open Access
- 1 January 2014
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 12 (1) , 3
Metformin and gonadotropins for ovulation induction in patients with polycystic ovary syndrome: a systematic review with meta-analysis of randomized controlled trials
The current systematic review with meta-analysis of randomized controlled trials (RCTs) was aimed to evaluate the effects of metformin on reproductive outcomes in patients with polycystic ovary syndrome (PCOS) who receive gonadotropins for ovulation induction. After systematic review of electronic databases and websites for registration of RCTs, a total of 7 RCTs reporting data on 1023 cycles were included in the final analysis. Descriptive data showed an overall low studies’ quality due to unclear sequence generation and allocation concealment, lack of blinding procedure, incomplete outcome data and several biases and/or confounders. Data synthesis showed that metformin improved live-birth (odds ratio [OR] = 1.94, 95% confidence interval [CI] 1.10 to 3.44; P = 0.020) and pregnancy (OR = 2.25, 95% CI 1.50 to 3.38; P < 0.0001) rates, without significant heterogeneity across the studies (P = 0.230, estimation of inconsistency = 30%; and P = 0.710, estimation of inconsistency = 0%, respectively, for live-birth and pregnancy rates). A significant reduction of cancellation rate was observed after metformin administration (OR = 0.41, 95% CI 0.24 to 0.72, P = 0.002) without significant heterogeneity across the studies (P = 0.500, estimation of inconsistency = 0%). Metformin administration influenced or did not influence other secondary endpoints assessed with a significant heterogeneity. In conclusion, metformin administration increases the live-birth and pregnancy rate in PCOS patients who receive gonadotropins for ovulation induction. Further well designed, blinded, placebo-controlled, and adequately powered RCTs are need to confirm that metanalytic results.
- 1 January 2014
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 12 (1) , 3
Open AccessMetformin and gonadotropins for ovulation induction in patients with polycystic ovary syndrome: a systematic review with meta-analysis of randomized controlled trials
The current systematic review with meta-analysis of randomized controlled trials (RCTs) was aimed to evaluate the effects of metformin on reproductive outcomes in patients with polycystic ovary syndrome (PCOS) who receive gonadotropins for ovulation induction. After systematic review of electronic databases and websites for registration of RCTs, a total of 7 RCTs reporting data on 1023 cycles were included in the final analysis. Descriptive data showed an overall low studies’ quality due to unclear sequence generation and allocation concealment, lack of blinding procedure, incomplete outcome data and several biases and/or confounders. Data synthesis showed that metformin improved live-birth (odds ratio [OR] = 1.94, 95% confidence interval [CI] 1.10 to 3.44; P = 0.020) and pregnancy (OR = 2.25, 95% CI 1.50 to 3.38; P < 0.0001) rates, without significant heterogeneity across the studies (P = 0.230, estimation of inconsistency = 30%; and P = 0.710, estimation of inconsistency = 0%, respectively, for live-birth and pregnancy rates). A significant reduction of cancellation rate was observed after metformin administration (OR = 0.41, 95% CI 0.24 to 0.72, P = 0.002) without significant heterogeneity across the studies (P = 0.500, estimation of inconsistency = 0%). Metformin administration influenced or did not influence other secondary endpoints assessed with a significant heterogeneity. In conclusion, metformin administration increases the live-birth and pregnancy rate in PCOS patients who receive gonadotropins for ovulation induction. Further well designed, blinded, placebo-controlled, and adequately powered RCTs are need to confirm that metanalytic results.
- Open Access
- 12 September 2013
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 6 (1) , 64
Pronuclear morphology evaluation for fresh in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) cycles: a systematic review
The current systematic review was aimed to assess the effectiveness of the zygote morphology evaluation in fresh in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) cycles. All available studies reporting on zygote morphology and clinical and/or biological outcomes were analyzed. Forty studies were included in the final analysis. Fourteen different zygote scoring systems were employed. Zygote morphology correlated significantly with embryo quality and cleavage, blastocyst stage, embryonic chromosome status, in a high proportion of the studies which assessed the specific outcome [15/25 (60%), 15/20 (75%), 7/8 (87.5%), 6/6 (100%), respectively]. On the other hand, only a reduced proportion of papers showed a statistically significant relationship between implantation, pregnancy and delivery/live-birth rates and zygote morphology score [12/23 (52.2%), 12/25 (48%), 1/4 (25%), respectively]. In conclusion, our findings demonstrate the lack of conclusive data on the clinical efficacy of the zygote morphology evaluation in fresh IVF/ICSI cycles, even if biological results showing a good relationship with embryo viability suggest a role in cycles in which the transfer/freezing is performed at day 1.
- 12 September 2013
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 6 (1) , 64
Open AccessPronuclear morphology evaluation for fresh in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) cycles: a systematic review
The current systematic review was aimed to assess the effectiveness of the zygote morphology evaluation in fresh in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) cycles. All available studies reporting on zygote morphology and clinical and/or biological outcomes were analyzed. Forty studies were included in the final analysis. Fourteen different zygote scoring systems were employed. Zygote morphology correlated significantly with embryo quality and cleavage, blastocyst stage, embryonic chromosome status, in a high proportion of the studies which assessed the specific outcome [15/25 (60%), 15/20 (75%), 7/8 (87.5%), 6/6 (100%), respectively]. On the other hand, only a reduced proportion of papers showed a statistically significant relationship between implantation, pregnancy and delivery/live-birth rates and zygote morphology score [12/23 (52.2%), 12/25 (48%), 1/4 (25%), respectively]. In conclusion, our findings demonstrate the lack of conclusive data on the clinical efficacy of the zygote morphology evaluation in fresh IVF/ICSI cycles, even if biological results showing a good relationship with embryo viability suggest a role in cycles in which the transfer/freezing is performed at day 1.
- 1 June 2013
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 8 (1) , 30-37
Clomiphene Citrate, Metformin or Both for Ovulation Induction in Therapy Naïve Women with Polycystic Ovary Syndrome (PCOS)? A Descriptive Review
Background: Early treatment for infertile women with polycystic ovary syndrome (PCOS) is likely crucial and includes mainly clomiphene citrate (CC) and metformin. Objectives: To review the literature data regarding the use of CC, metformin, or both for the treatment of infertility in anovulatory patients with PCOS. Materials and Methods: Using PubMed database, all main relevant articles studying therapy naïve patients with PCOS who received CC, metformin or both were searched, reviewed and analyzed. Main Results and Conclusions: In infertile obese PCOS patients, CC is the therapy of choice for inducing ovulation. Combining CC and metformin is not more effective than CC alone. Further studies are needed to define the best first line treatment in non-obese PCOS patients.
- 1 June 2013
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 8 (1) , 30-37
Clomiphene Citrate, Metformin or Both for Ovulation Induction in Therapy Naïve Women with Polycystic Ovary Syndrome (PCOS)? A Descriptive Review
Background: Early treatment for infertile women with polycystic ovary syndrome (PCOS) is likely crucial and includes mainly clomiphene citrate (CC) and metformin. Objectives: To review the literature data regarding the use of CC, metformin, or both for the treatment of infertility in anovulatory patients with PCOS. Materials and Methods: Using PubMed database, all main relevant articles studying therapy naïve patients with PCOS who received CC, metformin or both were searched, reviewed and analyzed. Main Results and Conclusions: In infertile obese PCOS patients, CC is the therapy of choice for inducing ovulation. Combining CC and metformin is not more effective than CC alone. Further studies are needed to define the best first line treatment in non-obese PCOS patients.
- 1 December 2012
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 67 (12) , 788-789
Decidual Endovascular Trophoblast Invasion in Women With Polycystic Ovary Syndrome
- 1 December 2012
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 67 (12) , 788-789
Decidual Endovascular Trophoblast Invasion in Women With Polycystic Ovary Syndrome
- 12 January 2012
- Published by Springer Nature
- p. 2031-2044
Presurgical Assessment of Intra-abdominal Visceral Fat in Obese Patients
- 12 January 2012
- Published by Springer Nature
- p. 2031-2044
Presurgical Assessment of Intra-abdominal Visceral Fat in Obese Patients
- Open Access
- 13 October 2010
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 3 (1) , 23
Changes in androgens and insulin sensitivity indexes throughout pregnancy in women with polycystic ovary syndrome (PCOS): relationships with adverse outcomes
Background: Given the high rate of pregnancy and perinatal complications recently observed in patients with polycystic ovary syndrome (PCOS) and the lack of data on the serum variations in androgens and insulin sensitivity indexes in pregnant women with PCOS, the current study was aimed to assess these changes and their potential effect on pregnancy outcomes in a population of women with PCOS. Methods: Forty-five pregnant patients with ovulatory PCOS (PCOS group) and other 42 healthy pregnant women (control group) were studied assaying serum androgen levels and insulin sensitivity indexes throughout pregnancy serially, and recording obstetrical outcomes. Results: Serum androgen levels and insulin resistance indexes were significantly (p < 0.05) higher in PCOS than in control group at study entry, these differences were sustained throughout pregnancy, and their changes resulted significantly (p < 0.05) different between PCOS and control group. In PCOS patients, women who had a complicated pregnancy showed serum androgen levels and insulin sensitivity indexes significantly (p < 0.05) worse in comparison to subjects without any pregnancy and/or neonatal complications. Conclusions: PCOS patients have impaired changes in serum androgen levels and insulin sensitivity indexes during pregnancy. These alterations could be implicated in the pregnancy and neonatal complications frequently observed in women affected by PCOS.
- 13 October 2010
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 3 (1) , 23
Open AccessChanges in androgens and insulin sensitivity indexes throughout pregnancy in women with polycystic ovary syndrome (PCOS): relationships with adverse outcomes
Background: Given the high rate of pregnancy and perinatal complications recently observed in patients with polycystic ovary syndrome (PCOS) and the lack of data on the serum variations in androgens and insulin sensitivity indexes in pregnant women with PCOS, the current study was aimed to assess these changes and their potential effect on pregnancy outcomes in a population of women with PCOS. Methods: Forty-five pregnant patients with ovulatory PCOS (PCOS group) and other 42 healthy pregnant women (control group) were studied assaying serum androgen levels and insulin sensitivity indexes throughout pregnancy serially, and recording obstetrical outcomes. Results: Serum androgen levels and insulin resistance indexes were significantly (p < 0.05) higher in PCOS than in control group at study entry, these differences were sustained throughout pregnancy, and their changes resulted significantly (p < 0.05) different between PCOS and control group. In PCOS patients, women who had a complicated pregnancy showed serum androgen levels and insulin sensitivity indexes significantly (p < 0.05) worse in comparison to subjects without any pregnancy and/or neonatal complications. Conclusions: PCOS patients have impaired changes in serum androgen levels and insulin sensitivity indexes during pregnancy. These alterations could be implicated in the pregnancy and neonatal complications frequently observed in women affected by PCOS.